Based in Zurich, Switzerland, Nextech Invest was founded in 1998 and specializes in early, mid-stage, and late-stage investments in life science and enabling technologies. The firm invests in companies developing cancer drugs and diagnostics, with a particular focus on interdisciplinary technical and scientific projects. Nextech Invest seeks investments in Europe, North America, the Middle East, and Asia, and typically invests between CHF 1 million and CHF 5 million per financing round. The firm aims to exit its investments within three years through trade sales. With 33 investments and 17 exits, Nextech Invest has a strong track record in the field of precision therapies in oncology.